Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH

Robert Cornell; Parameswaran Hari; Shijie Tang; Noa Biran; Natalie Callander; Ajai Chari; Saurabh Chhabra; Mark A. Fiala; Zhubin Gahvari; Ujjawal Gandhi; Kelly Godby; Ridhi Gupta; Sundar Jagannath; Megan Jagosky; Yubin Kang; Ankit Kansagra; Michael Kauffman; Saranya Kodali; Shaji K. Kumar; Arjun Lakshman; Michaela Liedtke; Sagar Lonial; Xiwen Ma; Ehsan Malek; Joshua Mansour; Elizabeth F. McGehee; Amarendra Neppalli; Barry Paul; Paul Richardson; Emma C. Scott; Sharon Shacham; Jatin Shah; David S. Siegel; Elvira Umyarova; Saad Z. Usmani; William Varnado; Ravi Vij; Luciano Costa

doi:10.1002/ajh.26010

Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH

Robert Cornell, Parameswaran Hari, Shijie Tang, Noa Biran, Natalie Callander, Ajai Chari, Saurabh Chhabra, Mark A. Fiala, Zhubin Gahvari, Ujjawal Gandhi, Kelly Godby, Ridhi Gupta, Sundar Jagannath, Megan Jagosky, Yubin Kang, Ankit Kansagra, Michael Kauffman, Saranya Kodali, Shaji K. Kumar, Arjun LakshmanMichaela Liedtke, Sagar Lonial, Xiwen Ma, Ehsan Malek, Joshua Mansour, Elizabeth F. McGehee, Amarendra Neppalli, Barry Paul, Paul Richardson, Emma C. Scott, Sharon Shacham, Jatin Shah, David S. Siegel, Elvira Umyarova, Saad Z. Usmani, William Varnado, Ravi Vij, Luciano Costa

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	E5-E8
Journal	American Journal of Hematology
Volume	96
Issue number	1
DOIs	https://doi.org/10.1002/ajh.26010
State	Published - Jan 2021

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26010

Cite this

Cornell, R., Hari, P., Tang, S., Biran, N., Callander, N., Chari, A., Chhabra, S., Fiala, M. A., Gahvari, Z., Gandhi, U., Godby, K., Gupta, R., Jagannath, S., Jagosky, M., Kang, Y., Kansagra, A., Kauffman, M., Kodali, S., Kumar, S. K., ... Costa, L. (2021). Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. American Journal of Hematology, 96(1), E5-E8. https://doi.org/10.1002/ajh.26010

Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. / Cornell, Robert; Hari, Parameswaran; Tang, Shijie; Biran, Noa; Callander, Natalie; Chari, Ajai; Chhabra, Saurabh; Fiala, Mark A.; Gahvari, Zhubin; Gandhi, Ujjawal; Godby, Kelly; Gupta, Ridhi; Jagannath, Sundar; Jagosky, Megan; Kang, Yubin; Kansagra, Ankit; Kauffman, Michael; Kodali, Saranya; Kumar, Shaji K.; Lakshman, Arjun; Liedtke, Michaela; Lonial, Sagar; Ma, Xiwen; Malek, Ehsan; Mansour, Joshua; McGehee, Elizabeth F.; Neppalli, Amarendra; Paul, Barry; Richardson, Paul; Scott, Emma C.; Shacham, Sharon; Shah, Jatin; Siegel, David S.; Umyarova, Elvira; Usmani, Saad Z.; Varnado, William; Vij, Ravi; Costa, Luciano.

In: American Journal of Hematology, Vol. 96, No. 1, 01.2021, p. E5-E8.

Research output: Contribution to journal › Letter › peer-review

Cornell, R, Hari, P, Tang, S, Biran, N, Callander, N, Chari, A, Chhabra, S, Fiala, MA, Gahvari, Z, Gandhi, U, Godby, K, Gupta, R, Jagannath, S, Jagosky, M, Kang, Y, Kansagra, A, Kauffman, M, Kodali, S, Kumar, SK, Lakshman, A, Liedtke, M, Lonial, S, Ma, X, Malek, E, Mansour, J, McGehee, EF, Neppalli, A, Paul, B, Richardson, P, Scott, EC, Shacham, S, Shah, J, Siegel, DS, Umyarova, E, Usmani, SZ, Varnado, W, Vij, R & Costa, L 2021, 'Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH', American Journal of Hematology, vol. 96, no. 1, pp. E5-E8. https://doi.org/10.1002/ajh.26010

Cornell, Robert ; Hari, Parameswaran ; Tang, Shijie ; Biran, Noa ; Callander, Natalie ; Chari, Ajai ; Chhabra, Saurabh ; Fiala, Mark A. ; Gahvari, Zhubin ; Gandhi, Ujjawal ; Godby, Kelly ; Gupta, Ridhi ; Jagannath, Sundar ; Jagosky, Megan ; Kang, Yubin ; Kansagra, Ankit ; Kauffman, Michael ; Kodali, Saranya ; Kumar, Shaji K. ; Lakshman, Arjun ; Liedtke, Michaela ; Lonial, Sagar ; Ma, Xiwen ; Malek, Ehsan ; Mansour, Joshua ; McGehee, Elizabeth F. ; Neppalli, Amarendra ; Paul, Barry ; Richardson, Paul ; Scott, Emma C. ; Shacham, Sharon ; Shah, Jatin ; Siegel, David S. ; Umyarova, Elvira ; Usmani, Saad Z. ; Varnado, William ; Vij, Ravi ; Costa, Luciano. / Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. In: American Journal of Hematology. 2021 ; Vol. 96, No. 1. pp. E5-E8.

@article{d7e8bc5e0c904fcb94b3d149b8652660,

title = "Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH",

author = "Robert Cornell and Parameswaran Hari and Shijie Tang and Noa Biran and Natalie Callander and Ajai Chari and Saurabh Chhabra and Fiala, {Mark A.} and Zhubin Gahvari and Ujjawal Gandhi and Kelly Godby and Ridhi Gupta and Sundar Jagannath and Megan Jagosky and Yubin Kang and Ankit Kansagra and Michael Kauffman and Saranya Kodali and Kumar, {Shaji K.} and Arjun Lakshman and Michaela Liedtke and Sagar Lonial and Xiwen Ma and Ehsan Malek and Joshua Mansour and McGehee, {Elizabeth F.} and Amarendra Neppalli and Barry Paul and Paul Richardson and Scott, {Emma C.} and Sharon Shacham and Jatin Shah and Siegel, {David S.} and Elvira Umyarova and Usmani, {Saad Z.} and William Varnado and Ravi Vij and Luciano Costa",

note = "Funding Information: We would like to especially thank all the patients who participated in the studies, and their families. The STORM study (NCT02336815) and the present analysis were funded by Karyopharm Therapeutics, Newton, Massachusetts. The MAMMOTH study was not commercially funded. The authors also acknowledge Liz Anfield, Prime Global, Knutsford, UK, for medical writing support, under the direction of the authors, which was funded by Karyopharm Therapeutics in accordance with Good Publications Practice (GPP3) guidelines. Development of this manuscript was supported by Karyopharm Therapeutics. Funding Information: R.C. reports honoraria from Karyopharm Therapeutics, Takeda, Janssen, Sanofi, and GlaxoSmithKline; P.H. reports honoraria from Bristol Myers Squibb, Takeda, Amgen, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Sanofi, and Pharmacyclics; S.T., J.S., M.K., and X.M. report being employed by and owning stock in Karyopharm Therapeutics; N.B. reports honoraria and speakers' bureau participation for Celgene, Amgen, Janssen, and Takeda; consulting or advisory role fees and reimbursement of travel, accommodations, or other expenses from Celgene, Amgen, and Takeda; and research funding from Merck and Amgen; N.C. reports research support from Cellectar; A.C. reports receiving grant support and consulting fees from Millennium/Takeda; grant support, advisory board fees, and consulting fees from Celgene, Novartis Pharmaceuticals, Amgen, and Janssen; consulting fees from Bristol Myers Squibb; advisory board fees from Sanofi and Oncopeptides; grant support from Pharmacyclics; and grant support and advisory board fees from Seattle Genetics; S.C. reports receiving honorarium from Takeda Pharmaceuticals; Funding Information: S.J. reports receiving advisory board fees and consulting fees from Bristol Myers Squibb, Janssen Pharmaceuticals, and Merck; Y.K. reports receiving advisory board fees from Takeda and grant support from InCyte; A.K. reports receiving advisory board fees from Celgene, Janssen, Karyopharm Therapeutics, Takeda, Pfizer and Pharmacyclics; S.K.K. reports receiving advisory board fees from AbbVie, Celgene, Janssen, Takeda Pharmaceuticals, Adaptive Biotechnologies, Kite Pharma, MedImmune/AstraZeneca; receiving research funding from AbbVie, Celgene, Janssen, Merck, Novartis, Roche, Sanofi, Takeda Pharmaceuticals, Kite Pharma and MedImmune/AstraZeneca; and is a member of the Independent Review Committee for Oncopeptides; M.L. reports receiving personal fees from Amgen, Celgene, Pfizer, Takeda, and Janssen; S.L. reports receiving advisory board fees from AbbVie, Amgen, Celgene, Takeda, Janssen Oncology, Juno Therapeutics, Novartis, Merck, Bristol Myers Squibb, and GlaxoSmithKline; and receiving research funding from Bristol Myers Squibb, Celgene, and Takeda; E.M. reports receiving advisory board and speaker fees from Takeda, Sanofi, Amgen and Celgene; speaker fees from Janssen; research funding from Medpacto Inc. and Cumberland; A.N. reports receiving advisory board fees from Amgen; B.P. reports receiving honoraria from Celgene; consulting fees from Amgen and Janssen; P.R. reports receiving grant support and honoraria from Oncopeptides, Celgene, and Takeda; grant support from Bristol Myers Squibb; and honoraria from Amgen, Janssen, and Karyopharm Therapeutics; E.S. reports being employed by GlaxoSmithKline; S.S. reports being employed by and owning stock in Karyopharm Therapeutics, holding patents (8 999 996, 9 079 865, 9 714 226, PCT/US12/048319, and I574957) on hydrazide‐containing nuclear transport modulators and uses, and holding pending patents (PCT/US12/048319, 499/2012, PI20102724, and 012000928) on hydrazide‐containing nuclear transport modulators and uses; D.S. reports receiving honoraria and consulting or advisory role fees for Celgene, Amgen, Merck, Janssen, Bristol Myers Squibb, Takeda, and Karyopharm Therapeutics; speakers' bureau participation for Celgene, Amgen, Merck, Janssen, Bristol Myers Squibb, and Takeda; and research funding from Celgene; S.U. reports receiving consulting fees from Abbvie, Amgen Inc, Bristol Myers Squibb, Celgene, EdoPharma, GlaxoSmithKline, Janssen, Merck, Sanofi, Seattle Genetics, Skyline Dx, Takeda, and TeneoBio; and research funding from Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, Janssen, Merck, Pharmacyclics, Prothena, Sanofi, Seattle Genetics, Skyline Dx, and Takeda; R.V. reports receiving advisory board fees from Bristol Myers Squibb, Takeda, Janssen, Karyopharm Therapeutics, Securabio, and Genentech; and research funding from Bristol Myers Squibb and Takeda; L.C. reports research funding from Amgen and Janssen; and honoraria from Karyopharm Therapeutics, Celgene, Amgen, Janssen, and Sanofi. M.F., Z.G., U.G., K.G., R.G., M.J., S.K., A.L., J.M., E.F.M., E.U., and W.V. declare no conflict of interest. ",

year = "2021",

month = jan,

doi = "10.1002/ajh.26010",

language = "English (US)",

volume = "96",

pages = "E5--E8",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH

AU - Cornell, Robert

AU - Hari, Parameswaran

AU - Tang, Shijie

AU - Biran, Noa

AU - Callander, Natalie

AU - Chari, Ajai

AU - Chhabra, Saurabh

AU - Fiala, Mark A.

AU - Gahvari, Zhubin

AU - Gandhi, Ujjawal

AU - Godby, Kelly

AU - Gupta, Ridhi

AU - Jagannath, Sundar

AU - Jagosky, Megan

AU - Kang, Yubin

AU - Kansagra, Ankit

AU - Kauffman, Michael

AU - Kodali, Saranya

AU - Kumar, Shaji K.

AU - Lakshman, Arjun

AU - Liedtke, Michaela

AU - Lonial, Sagar

AU - Ma, Xiwen

AU - Malek, Ehsan

AU - Mansour, Joshua

AU - McGehee, Elizabeth F.

AU - Neppalli, Amarendra

AU - Paul, Barry

AU - Richardson, Paul

AU - Scott, Emma C.

AU - Shacham, Sharon

AU - Shah, Jatin

AU - Siegel, David S.

AU - Umyarova, Elvira

AU - Usmani, Saad Z.

AU - Varnado, William

AU - Vij, Ravi

AU - Costa, Luciano

N1 - Funding Information: We would like to especially thank all the patients who participated in the studies, and their families. The STORM study (NCT02336815) and the present analysis were funded by Karyopharm Therapeutics, Newton, Massachusetts. The MAMMOTH study was not commercially funded. The authors also acknowledge Liz Anfield, Prime Global, Knutsford, UK, for medical writing support, under the direction of the authors, which was funded by Karyopharm Therapeutics in accordance with Good Publications Practice (GPP3) guidelines. Development of this manuscript was supported by Karyopharm Therapeutics. Funding Information: R.C. reports honoraria from Karyopharm Therapeutics, Takeda, Janssen, Sanofi, and GlaxoSmithKline; P.H. reports honoraria from Bristol Myers Squibb, Takeda, Amgen, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Sanofi, and Pharmacyclics; S.T., J.S., M.K., and X.M. report being employed by and owning stock in Karyopharm Therapeutics; N.B. reports honoraria and speakers' bureau participation for Celgene, Amgen, Janssen, and Takeda; consulting or advisory role fees and reimbursement of travel, accommodations, or other expenses from Celgene, Amgen, and Takeda; and research funding from Merck and Amgen; N.C. reports research support from Cellectar; A.C. reports receiving grant support and consulting fees from Millennium/Takeda; grant support, advisory board fees, and consulting fees from Celgene, Novartis Pharmaceuticals, Amgen, and Janssen; consulting fees from Bristol Myers Squibb; advisory board fees from Sanofi and Oncopeptides; grant support from Pharmacyclics; and grant support and advisory board fees from Seattle Genetics; S.C. reports receiving honorarium from Takeda Pharmaceuticals; Funding Information: S.J. reports receiving advisory board fees and consulting fees from Bristol Myers Squibb, Janssen Pharmaceuticals, and Merck; Y.K. reports receiving advisory board fees from Takeda and grant support from InCyte; A.K. reports receiving advisory board fees from Celgene, Janssen, Karyopharm Therapeutics, Takeda, Pfizer and Pharmacyclics; S.K.K. reports receiving advisory board fees from AbbVie, Celgene, Janssen, Takeda Pharmaceuticals, Adaptive Biotechnologies, Kite Pharma, MedImmune/AstraZeneca; receiving research funding from AbbVie, Celgene, Janssen, Merck, Novartis, Roche, Sanofi, Takeda Pharmaceuticals, Kite Pharma and MedImmune/AstraZeneca; and is a member of the Independent Review Committee for Oncopeptides; M.L. reports receiving personal fees from Amgen, Celgene, Pfizer, Takeda, and Janssen; S.L. reports receiving advisory board fees from AbbVie, Amgen, Celgene, Takeda, Janssen Oncology, Juno Therapeutics, Novartis, Merck, Bristol Myers Squibb, and GlaxoSmithKline; and receiving research funding from Bristol Myers Squibb, Celgene, and Takeda; E.M. reports receiving advisory board and speaker fees from Takeda, Sanofi, Amgen and Celgene; speaker fees from Janssen; research funding from Medpacto Inc. and Cumberland; A.N. reports receiving advisory board fees from Amgen; B.P. reports receiving honoraria from Celgene; consulting fees from Amgen and Janssen; P.R. reports receiving grant support and honoraria from Oncopeptides, Celgene, and Takeda; grant support from Bristol Myers Squibb; and honoraria from Amgen, Janssen, and Karyopharm Therapeutics; E.S. reports being employed by GlaxoSmithKline; S.S. reports being employed by and owning stock in Karyopharm Therapeutics, holding patents (8 999 996, 9 079 865, 9 714 226, PCT/US12/048319, and I574957) on hydrazide‐containing nuclear transport modulators and uses, and holding pending patents (PCT/US12/048319, 499/2012, PI20102724, and 012000928) on hydrazide‐containing nuclear transport modulators and uses; D.S. reports receiving honoraria and consulting or advisory role fees for Celgene, Amgen, Merck, Janssen, Bristol Myers Squibb, Takeda, and Karyopharm Therapeutics; speakers' bureau participation for Celgene, Amgen, Merck, Janssen, Bristol Myers Squibb, and Takeda; and research funding from Celgene; S.U. reports receiving consulting fees from Abbvie, Amgen Inc, Bristol Myers Squibb, Celgene, EdoPharma, GlaxoSmithKline, Janssen, Merck, Sanofi, Seattle Genetics, Skyline Dx, Takeda, and TeneoBio; and research funding from Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, Janssen, Merck, Pharmacyclics, Prothena, Sanofi, Seattle Genetics, Skyline Dx, and Takeda; R.V. reports receiving advisory board fees from Bristol Myers Squibb, Takeda, Janssen, Karyopharm Therapeutics, Securabio, and Genentech; and research funding from Bristol Myers Squibb and Takeda; L.C. reports research funding from Amgen and Janssen; and honoraria from Karyopharm Therapeutics, Celgene, Amgen, Janssen, and Sanofi. M.F., Z.G., U.G., K.G., R.G., M.J., S.K., A.L., J.M., E.F.M., E.U., and W.V. declare no conflict of interest.

PY - 2021/1

Y1 - 2021/1

UR - http://www.scopus.com/inward/record.url?scp=85092920395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092920395&partnerID=8YFLogxK

U2 - 10.1002/ajh.26010

DO - 10.1002/ajh.26010

M3 - Letter

C2 - 32974944

AN - SCOPUS:85092920395

VL - 96

SP - E5-E8

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -